Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION
6.1.2 INCREASING GERIATRIC POPULATION
6.1.3 INCREASE IN PIPELINE PRODUCTS
6.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS
6.2 RESTRAINTS
6.2.1 HIGH COST OF TREATMENT AND PROCEDURES
6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 INCREASING RESEARCH AND DEVELOPMENT
6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD
6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT
6.3.4 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD)
6.4 CHALLENGES
6.4.1 LIMITED ACCESS TO TREATMENT
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS
7 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE
7.1 OVERVIEW
7.2 DRY AMD
7.3 WET AMD
7.3.1 MEDICATIONS
7.3.2 ANTI-VEGF THERAPY
7.3.3 GENE THERAPY
7.3.4 SURGERY
8 MIDDLE EAST & AFRICA AGE- RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 SPECIALTY CLINICS
8.4 AMBULATORY SURGICAL CENTERS
8.5 HOME HEALTHCARE
8.6 OTHERS
9 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 RETAIL SALES
9.2.1 HOSPITAL PHARMACIES
9.2.2 RETAIL PHARMACIES
9.2.3 OTHERS
9.3 DIRECT TENDER
10 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION
10.1 MIDDLE EAST & AFRICA
10.1.1 SOUTH AFRICA
10.1.2 SAUDI ARABIA
10.1.3 UAE
10.1.4 ISRAEL
10.1.5 EGYPT
10.1.6 KUWAIT
10.1.7 REST OF MIDDLE EAST & AFRICA
11 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 NOVARTIS AG
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENT
13.1.5.1 AGREEMENT
13.2 GENENTECH, INC.
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENT
13.3 BAYER AG
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENT
13.4 ADVERUM BIOTECHNOLOGIES, INC.
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENT
13.5 ASTELLAS PHARMA INC.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENT
13.6 GRAYBUG VISION INC.
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENT
13.7 GENSIGHT BIOLOGICS
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.7.4.1 EVENT
13.7.4.2 AWARD
13.8 IONIS PHARMACEUTICALS
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENT
13.8.4.1 EVENT
13.9 IVERIC BIO
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.1 JOHNSON &JOHNSON SERVICES, INC.
13.10.1 COMPANY SNAPSHOT
13.10.2 REVENUE ANALYSIS
13.10.3 PRODUCT PORTFOLIO
13.10.4 RECENT DEVELOPMENT
13.10.4.1 COLLABORATION
13.11 KODIAK SCIENCES INC.
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
13.12 MEIRAGTX LIMITED
13.12.1 COMPANY SNAPSHOT
13.12.2 PRODUCT PORTFOLIO
13.12.3 RECENT DEVELOPMENTS
13.12.3.1 EVENTS
13.12.3.2 AWARD
13.12.3.3 COLLABORATION
13.13 OCUGEN INC.
13.13.1 COMPANY SNAPSHOT
13.13.2 PRODUCT PORTFOLIO
13.13.3 RECENT DEVELOPMENTS
13.13.3.1 INVESTMENT
13.13.3.2 CLINICAL TRIAL
13.14 PIXIUM VISION
13.14.1 COMPANY SNAPSHOT
13.14.2 REVENUE ANALYSIS
13.14.3 PRODUCT PORTFOLIO
13.14.4 RECENT DEVELOPMENT
13.14.4.1 AWARD
13.15 REGENXBIO INC.
13.15.1 COMPANY SNAPSHOT
13.15.2 PRODUCT PORTFOLIO
13.15.3 RECENT DEVELOPMENTS
13.15.3.1 EVENT
13.15.3.2 COLLABORATION
13.15.3.3 CERTIFICATION
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
TABLE 1 VARIOUS EXAMPLES OF OPHTHALMIC DEVICES ARE SUMMARIZED IN THE BELOW-GIVEN TABLE ACCORDING TO THEIR CLASSIFICATION
TABLE 2 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 24 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 SOUTH AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 26 SOUTH AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 29 SOUTH AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 30 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 SAUDI ARABIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 SAUDI ARABIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 SAUDI ARABIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 36 UAE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 UAE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 UAE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 UAE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 40 UAE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 41 UAE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 ISRAEL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 ISRAEL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 45 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 46 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 47 ISRAEL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 48 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 EGYPT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 EGYPT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 52 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 EGYPT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 54 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 KUWAIT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 KUWAIT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 58 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 59 KUWAIT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 60 REST OF MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRY AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET
FIGURE 16 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2021
FIGURE 17 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2021
FIGURE 21 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 23 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, LIFELINE CURVE
FIGURE 24 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 25 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 27 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 28 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SNAPSHOT (2021)
FIGURE 29 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2021)
FIGURE 30 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2022 & 2029)
FIGURE 31 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2021 & 2029)
FIGURE 32 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE (2022-2029)
FIGURE 33 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY SHARE 2021 (%)
